Evrysdi

Treatment with Evrysdi must be started by a doctor experienced in treating SMA. The medicine can only be obtained with a prescription.

Evrysdi is taken by mouth once a day after a meal, at around the same time each day. In patients who are not able to swallow, Evrysdi can be given via a tube through the nose or skin to the stomach. The dose is based on the patient’s age and weight.

For more information about using Evrysdi, see the package leaflet or contact your doctor or pharmacist.

Patients with SMA lack a protein called ‘survival motor neuron’ (SMN) protein, which is essential for motor neurons (nerve cells in the spinal cord that control muscle movement) to continue working normally. Two genes, SMN1 and SMN2, are involved in the production of the SMN protein. Patients with SMA lack the SMN1 gene but have one or more copies of the SMN2 gene, which mostly produce a short SMN protein that does not work as well as the full-length protein.

The active substance in Evrysdi, risdiplam, is a small molecule that allows the SMN2 gene to produce the full-length protein, which can work normally. This is expected to increase survival of motor neurons, thereby reducing current symptoms of the disease and slowing down its progression.

Evrysdi was shown to be effective at improving motor function in 2 main studies in patients with SMA.

One study conducted in 41 infants aged 2 to 7 months with type 1 SMA (the most severe type) shows that 29% (12 out of 41) of infants were able to sit without support for more than 5 seconds after 12 months of treatment with Evrysdi. Past observations of infants with SMA found that they are never able to sit without support.

A second study in 180 patients with type 2 and type 3 SMA up to 25 years of age showed a slight improvement in motor function (as measured using a rating scale called MFM32) in patients treated with Evrysdi: there was a 1.6-point difference compared with placebo (a dummy treatment) on a 100-point scale after 12 months of treatment.

The most common side effects with Evrysdi (which may affect more than 1 in 10 people) are fever, rash, diarrhoea and headache.

For the full list of side effects of Evrysdi, see the package leaflet.

The effects of Evrysdi on the development of motor function in patients with SMA type 1, 2 and 3 were considered relevant, particularly considering the severity of the disease. In children with type 1 SMA, the most severe form of the disease, Evrysdi allows infants to sit without support for more than 5 seconds after a year of treatment, which they would not be able to do without treatment.

Evrysdi is also beneficial in patients with a later onset of SMA (type 2 and 3), although the effects in these patients are modest. The side effects with Evrysdi are considered manageable. Therefore, the European Medicines Agency decided that Evrysdi’s benefits are greater than its risks and it can be authorised for use in the EU.

The company that markets Evrysdi will provide data from a long-term study on the effects of the medicine in patients with up to 4 copies of the SMN2 gene compared with how the disease progresses in patients who have not been treated with Evrysdi.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Evrysdi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Evrysdi are continuously monitored. Side effects reported with Evrysdi are carefully evaluated and any necessary action taken to protect patients.

Evrysdi received a marketing authorisation valid throughout the EU on 26 March 2021.